Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
465-01-002 ISMRM Abstract

Probing intratumoral metabolic compartmentalisation in FHd-RCC using clinical HP 13C-MRI and MSI

Primary: Contrast Mechanisms - Hyperpolarized MR (Non-Gas)
Secondary: Body - Kidney
465-01-002 · Hyperpolarization: Novel Applications · Tuesday, 12 May, 8:20 AM–9:15 AM · Digital Posters Row F
Keywords: Genetics Hyperpolarized 13C MRI Kidney cancer Abdominal MRI Mass spectrometry
Accepted
Ines Horvat-Menih 1, Ruth Casey, James Denholm, Gregory Hamm, Heather Hulme, John Gallon, Alixander S Khan1,2, Joshua D Kaggie1, Andrew B Gill, Andrew N Priest1,3, Joao A Duarte, Cissy Yong, Cara Brodie, James Whitworth, Simon T Barry, Richard J Goodwin, Shubha Anand, Marc Dodd, Katherine Honan, Sarah Welsh, Anne Warren, Tevita Aho, Grant D Stewart, Thomas J Mitchell, Mary A McLean1, Ferdia Gallagher1
1Department of Radiology, University of Cambridge, Cambridge, United Kingdom
2MR Research Centre, Aarhus University, Aarhus, Denmark
3NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
Presenting Author: Ines Horvat-Menih

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Kidney Cancer : Principles and Practice / Primo N. Lara, Jr., Eric Jonasch, Editors. (2015).
2. Yang, M., Soga, T., Pollard, P. J. & Adam, J. The emerging role of fumarate as an oncometabolite. Front Oncol 2, 85 (2012).
3. Bex, A. et al. EAU Guidelines: Renal Cell Carcinoma. Uroweb https://uroweb.org/guideline/renal-cell-carcinoma/.
4. Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 30, 706–720 (2019).
5. Forde, C. et al. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals. European Urology Oncology 3, 764–772 (2020).
6. Ursprung, S. et al. Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study. Cancers 14, 335 (2022).
7. Tang, S. et al. Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors—Initial experience. Cancer cncr.33554 (2021) doi:10.1002/cncr.33554. [doi]
8. Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 1, PO.17.00011 (2017).
9. Courcier, J. et al. Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. Int J Mol Sci 21, 7146 (2020).
10. Wang, T. et al. Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report. Front. Oncol. 11, 735077 (2021).
11. Zhang, X. et al. Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis. Transl Androl Urol 10, 4304–4312 (2021).
12. Sun, G. et al. Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma. Clin Cancer Res 27, 1734–1743 (2021).
13. DePeaux, K. & Delgoffe, G. M. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol 21, 785–797 (2021).
14. Horvat-Menih, I. et al. K-Means Clustering of Hyperpolarised 13C-MRI Identifies Intratumoral Perfusion/Metabolism Mismatch in Renal Cell Carcinoma as the Best Predictor of the Highest Grade. Cancers 17, 569 (2025).

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/465-01-002